-+ 0.00%
-+ 0.00%
-+ 0.00%

JOHNSON & JOHNSON ANNOUNCES U.S. FDA APPROVAL OF RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) AS FIRST AND ONLY DUAL-TARGETED THERAPY FOR ADVANCED HEAD AND NECK CANCER

Reuters·11/06/2026 02:03:45

Please log in to view news